SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

AVAX TECHNOLOGIES INC (AVXT)

AVXT RSS Feed
Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 10/4/2017 12:06:54 PM - Followers: 32 - Board type: Free - Posts Today: 0

 

Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
 
 
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

 


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


 

Press Releases & AVAX Information:

https://en.wikipedia.org/wiki/Avax_Technologies

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3551891/

http://www.ncbi.nlm.nih.gov/pubmed/22854662

http://www.clinicaltrials.gov/ct2/show/NCT00477906?term=MVax&rank=1

http://clinicaltrials.gov/show/NCT00660101

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20130309271&OS=20130309271&RS=20130309271

http://www.biotechblog.org/Tags/cancer-treatment-centers-of-america/

http://www.thefreelibrary.com/AVAX+Technologies+Announces+Collaboration+with+Cancer+Treatment...-a0159564876

http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108

http://ih.advfn.com/p.php?pid=nmona&article=61013370

http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html

http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing

 
By

Published: Aug 4, 2015 7:31 p.m. ET

Share
 
 
 
 

PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.


AVAX TECHNOLOGIES WEBSITE IS NOW ACTIVE:    WWW.AVAX-TECH.COM/
 

AVAX TECHNOLOGIES, INC APPOINTS NEW CEO: ADELE SOMMERFELD 10/19/2015
http://www.prnewswire.com/news-releases/avax-technologies-inc-announces-the-appointment-of-chief-executive-officer-300161646.html



 

SureTrader
Interactive Brokers Advertisement
AVXT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#1533   Someone just sold 166 shares at .002.... LMAO! cuckoo 4 cocoa puffs 10/04/17 12:06:54 PM
#1532   The website sometimes appears completely white and sometimes tencoin 10/03/17 02:38:41 PM
#1531   Ha! That's great news; thanks for updating us!. cuckoo 4 cocoa puffs 10/03/17 10:26:02 AM
#1530   News ! tencoin 10/03/17 05:14:13 AM
#1529   How can you be so optimistic? tencoin 10/02/17 11:04:10 AM
#1528   I would like to give a big thank cuckoo 4 cocoa puffs 10/02/17 10:27:05 AM
#1527   I'm not sure what's going on with the cuckoo 4 cocoa puffs 09/29/17 09:49:35 AM
#1526   I just got the same result. cuckoo 4 cocoa puffs 09/28/17 02:20:55 PM
#1525   AVAX website is disappeared ... tencoin 09/27/17 09:47:46 AM
#1524   Level II is incredibly thin... After we clear cuckoo 4 cocoa puffs 09/26/17 03:05:07 PM
#1523   This is looking real good! Slapping that ASK! cuckoo 4 cocoa puffs 09/26/17 03:01:36 PM
#1522   CDEL is now on the ask at 4 cuckoo 4 cocoa puffs 09/01/17 09:46:08 AM
#1521   cuckoo 4 cocoa puffs 09/01/17 09:46:02 AM
#1520   Thanks to whomever just sold me 101,688 shares cuckoo 4 cocoa puffs 09/01/17 09:41:58 AM
#1519   Nice ask slapping at for 225k @ .004 cuckoo 4 cocoa puffs 08/30/17 09:52:58 AM
#1518   Has anyone noticed CSTI parked at .25? cuckoo 4 cocoa puffs 08/29/17 06:30:37 PM
#1517   Silent treatment ha.... Lol. Believe me I've suffered cuckoo 4 cocoa puffs 08/29/17 06:27:29 PM
#1516   Nice pick up of 100k more shares this cuckoo 4 cocoa puffs 08/29/17 12:38:08 PM
#1515   Level two looking solid; next leg up is .004! cuckoo 4 cocoa puffs 08/28/17 03:34:57 PM
#1514   It's ASK SLAPPING TIME!!! $AVTX... cuckoo 4 cocoa puffs 08/25/17 06:24:19 PM
#1513   Looks like the hole has been dug in johnny canuck 08/22/17 12:59:41 PM
#1512   F#&K!!!!!!!!!!!!!!!!! Geoman1 08/18/17 12:01:13 PM
#1511   Crooks? Just my opinion. johnny canuck 06/23/17 01:32:06 PM
#1510   How could they allow 20 years of research Geoman1 06/19/17 11:02:53 AM
#1509   All that is going on is someone (MM?) johnny canuck 06/15/17 11:06:12 PM
#1508   Is anyone still alive or has this crapper Geoman1 05/24/17 10:59:01 AM
#1507   Unfortunately on link there are old data, the tencoin 03/09/17 06:34:22 AM
#1506   Unfortunately on link there are old data, the tencoin 03/09/17 06:25:36 AM
#1505   http://speculatingstocks.com/stockcomparison/versus.php?stock1=19576&stock2=8729 katter 03/09/17 12:29:18 AM
#1504   Geo man katter 03/08/17 02:49:19 PM
#1503   shares of AVAX Technologies Inc (AVXT) have seen katter 03/08/17 02:44:46 PM
#1502   they will take what is left, take the akika 02/22/17 08:34:49 PM
#1501   $320.00 left out of 100 Grand...all time low Geoman1 02/21/17 03:52:03 PM
#1500   I first found this one after my TTNP experience. Zilla 02/18/17 12:13:19 PM
#1499   18 plus years Zilla and I have been Geoman1 02/18/17 12:12:46 AM
#1498   Wow been a long time to have anything Zilla 02/17/17 03:22:43 PM
#1497   $350.00 out of 100 G's....all-time low today for Geoman1 02/16/17 10:26:18 AM
#1496   I think the company is flatlined. $114 worth johnny canuck 02/07/17 11:42:57 PM
#1495   Does anybody have any idea what the hell Geoman1 02/07/17 05:19:07 PM
#1494   $390.00 left out of 100G's....how the heck do Geoman1 02/02/17 01:18:44 AM
#1493   Google alert mentions....cancer research company comparison... katter 02/02/17 12:09:23 AM
#1492   $400.00 out of 100 G's left....hit the all-time Geoman1 01/27/17 02:31:34 PM
#1491   I have at least 42k in, started after katter 01/21/17 11:43:29 AM
#1490   $425.00 left out of 100g's....unbelievable...not one word in Geoman1 01/20/17 06:04:31 PM
#1489   $450.00 left out of 100G's Geoman1 01/19/17 11:19:33 PM
#1488   $475.00 left out of 100G's.... Geoman1 01/09/17 08:20:15 PM
#1487   Excuse me...$500.00 left out of 100 G's. The Geoman1 01/03/17 08:35:30 PM
#1486   $750.00 left out of 100G's. This dog is Geoman1 01/03/17 02:01:19 PM
#1485   Take it you MF's!..Come on take it all! Geoman1 12/14/16 07:20:50 PM
#1484   $1000.00 left out of 100 G's...burn baby burn....we Geoman1 12/13/16 09:57:24 AM
PostSubject